Moderna raises projected vaccine revenue to $19.2 billion in 2021

Pfizer forecasts a $26 billion profit on its drug sales.

The American company Moderna on Thursday increased by 4.3% – to $19.2 billion – its forecast revenue in 2021 from sales of its COVID-19 vaccine. Reuters news agency reported this.

According to him, in February, the company predicted a profit from the sale of the drug for $18.4 billion. The reason for the change in expectations, as indicated, was the increased demand for the company’s vaccine in some countries.

Another American company – Pfizer, which produces a coronavirus vaccine together with Germany’s BioNTech – forecasts a profit from the sale of its drug in the current year of $26 billion.

At the World Vaccine Congress Washington 2021, held on Wednesday via videoconference, Moderna was recognized as the world’s best COVID-19 vaccine. Moderna was also awarded for “Best New Vaccine Technology / Platform.” According to the congress website, the vaccine developed by Pfizer and BioNTech “received a very high rating.” The shortlist includes Sputnik V, as well as a drug developed by the British-Swedish company AstraZeneca in cooperation with the University of Oxford.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Author: Steve Cowan
Graduated From Princeton University. He has been at the Free Press since October 2014. Previously worked as a regional entertainment editor.
Function: Chief-Editor
Steve Cowan

Spelling error report

The following text will be sent to our editors:

30 number 0.286601 time